169880-40-4

Basic information

• Product Name: N-(2-methylthio-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine
• Synonyms: N-(2-methylthio-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine
• CAS NO: 169880-40-4
• Molecular Weight: 315.483
• Mol File: 169880-40-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(2-methylthio-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-methylthio-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine(169880-40-4)
• EPA Substance Registry System: N-(2-methylthio-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine(169880-40-4)

Safety Data

• Hazardous Substances Data: 169880-40-4(Hazardous Substances Data)

Upstream product

• 169882-90-0 2-N-(2-bromo-4-(1-methylethyl)phenyl)-4,6-dimethyl-2-pyrimidinamine 
• 108-79-2 4,6-dimethyl-2(1H)-pyrimidinone 
• 51605-97-1 2-bromo-4-isopropylaniline 
• 4472-44-0 2-chloro-4,6-dimethylpyrimidine 
• 624-92-0 Dimethyldisulphide 
• 169882-41-1 N-(2-bromo-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine 
• 169883-28-7 2-(4,6-dimethyl-pyrimidin-2-ylsulfanyl)-4-isopropyl-phenylamine 
• 1027912-20-4 2-(4,6-dimethyl-pyrimidin-2-ylamino)-5-isopropyl-benzenethiol 
• 76842-15-4 2-iodo-4-isopropylaniline 
• 22325-27-5 4,6-dimethyl-2-meraptopyrimidine 
• 75-03-6 ethyl iodide 
• 1027923-75-6 (4,6-dimethyl-pyrimidin-2-yl)-(4-isopropyl-2-methylsulfanyl-phenyl)-amine 

Downstream Products

• 169880-90-4 N-(2-methylsulfinyl-4-(1-methylethyl)phenyl)-N-ethyl-4,6-dimethyl-2-pyrimidinamine 

Relevant articles and documents

1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R 1, R 3, R 4, R 5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure activity relationships of 2-anilinopyrimidines and -triazines

Screening of our chemical library using a rat corticotropin-releasing hormone (CRH) receptor assay led to the discovery that 2-anilinopyrimidine 15-1 weakly displaced [125I]-0-Tyr-oCRH from rat frontal cortex homogenates when compared to the known peptide antagonist α-helical CRH(9- 41) (K(i) = 5700 nM vs 1 nM). Furthermore, 15-1 weakly inhibited CRH- stimulated adenylate cyclase activity in the same tissue, but it was less potent than α-helical CRH(9-41) (IC50 = 20 000 nM vs 250 nM). Systematic structure-activity relationship studies, using the cloned human CRH1 receptor assay, defined the pharmacophore for optimal binding to hCRH1 receptors. Several high-affinity 2-anilinopyrimidines and -triazines were discovered, some of which had superior pharmacokinetic profiles in the rat. This paper describes the structure-activity studies which improved hCRH1 receptor binding affinity and pharmacokinetic parameters in the rat. Compound 28-17 (mean hCRH(1)K(1) = 32 nM) had a significantly improved pharmacokinetic profile in the rat (19% oral bioavailability at 30 mg/kg) as well as in the dog (20% oral bioavailability at 5 mg/kg) relative to the early lead structures.